biologics. Its programs span cardiovascular-renal-metabolic indications such as diabetes, obesity, and hypertension, as well as oncology, immunology, neurology, and ophthalmology. The organization reports multiple U.S. patent applications and allowed patents for AI-based protein and drug design methods and platforms. It targets both pre-clinical and clinical drug candidate generation and optimization for safety and efficacy profiles.